B-cell maturation antigen (BCMA)-targeted antibody–drug conjugates (ADCs) have emerged as promising therapies for relapsed/refractory multiple myeloma (RRMM), but the overall efficacy and safety profile is unclear. This evidence concerns the gene TNFRSF17 and plasma cell myeloma.